Schilsky Richard L
American Society of Clinical Oncology, Alexandria, Virginia 22314, USA.
Ecancermedicalscience. 2015 Aug 13;9:564. doi: 10.3332/ecancer.2015.564. eCollection 2015.
The worldwide innovative networking (WIN) consortium comprises a global alliance of 28 academic and clinical cancer centres, 11 pharmaceutical and technology companies and five charitable or health payer organisations. Since its inception the consortium has striven to provide a forum for all of its members to network, share information and experience, and perform clinical trials with the overarching goal of advancing the care of patients with cancer through the use of precision medicine. The annual 2-day WIN Symposium is the most visible output of the consortium and provides an opportunity for around 400 experts and other delegates to meet and discuss the latest research and initiatives in personalised cancer medicine. The seventh WIN Symposium, held in Paris, France, 29-30 June 2015, consisted of nine plenary and eight poster sessions that covered the overarching theme of novel targets, innovative agents, and advanced technologies being a winning strategy. Highlights included discussions of immune mechanisms and ways to target the cancer immunome and systems biology approaches to supporting personalised cancer. The latest data from the BATTLE-2 and WINther trials were discussed, and round table discussions were held that focused on how best to design the next generation of clinical trials, which included SPRING, SUMMER, and BOOSTER being initiated by the WIN Consortium.
全球创新网络（WIN）联盟由28个学术和临床癌症中心、11家制药和科技公司以及5个慈善或医疗支付机构组成的全球联盟。自成立以来，该联盟一直致力于为所有成员提供一个交流网络、分享信息和经验以及开展临床试验的平台，其总体目标是通过精准医疗改善癌症患者的治疗。为期两天的年度WIN研讨会是该联盟最引人注目的成果，为约400名专家和其他代表提供了一个会面并讨论个性化癌症医学最新研究和倡议的机会。2015年6月29日至30日在法国巴黎举行的第七届WIN研讨会包括9场全会和8场海报展示，涵盖了新型靶点、创新药物和先进技术作为制胜策略这一总体主题。亮点包括对免疫机制以及针对癌症免疫组的方法和支持个性化癌症的系统生物学方法的讨论。会上讨论了BATTLE - 2和WINther试验的最新数据，并举行了圆桌讨论，重点是如何最好地设计下一代临床试验，其中包括WIN联盟发起的SPRING、SUMMER和BOOSTER试验。
